Personensuche
Personensuche
Es wurde 1 Person gefunden.
Funktionen
-
Assistenzarzt/-ärztin, Klinik für Dermatologie
Aktuelle Veranstaltungen
Vergangene Veranstaltungen (max. 10)
-
SoSe 2025
-
WiSe 2024
-
SoSe 2024
-
WiSe 2023
-
SoSe 2023
-
WiSe 2022
-
SoSe 2022
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
A new approach combining a whole-slide foundation model and gradient boosting for predicting BRAF mutation status in dermatopathologyIn: Computational and Structural Biotechnology Journal, Jg. 27, 2025, S. 2503 – 2514DOI (Open Access)
-
Behandlung des metastasierten Melanoms : Update 2025In: Aktuelle Dermatologie, Jg. 51, 2025, Nr. 7, S. 256 – 264
-
Behandlung des metastasierten Melanoms : Update 2025In: Deutsche Medizinische Wochenschrift - DMW, Jg. 150, 2025, Nr. 10, S. 562 – 569
-
Clinical course of Merkel cell carcinoma : A DeCOG multicenter study of 1049 patientsIn: European Journal of Cancer (EJC), Jg. 221, 2025, 115406
-
Comparative analysis of international melanoma guidelinesIn: EJC Skin Cancer, Jg. 3, 2025, 100732DOI (Open Access)
-
Correction : Fully volumetric body composition analysis for prognostic overall survival stratification in melanoma patientsIn: Journal of Translational Medicine, Jg. 23, 2025, Nr. 1, 596DOI (Open Access)
-
First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma : A multicenter study from the prospective skin cancer registry ADOREGIn: European Journal of Cancer (EJC), Jg. 220, 2025, 115356DOI (Open Access)
-
Fully volumetric body composition analysis for prognostic overall survival stratification in melanoma patientsIn: Journal of Translational Medicine, Jg. 23, 2025, Nr. 1, 532DOI (Open Access)
-
Glomuvenous MalformationsIn: Deutsches Ärzteblatt International, Jg. 122, 2025, Nr. 12, S. 327DOI (Open Access)
-
Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients with Stage III MelanomaIn: Journal of Clinical Oncology (JCO), Jg. 43, 2025, Nr. 25, S. 2793 – 2805
-
Outcome of systemic therapy in patients with advanced rare skin cancers : A retrospective multicenter DeCOG study of 209 patientsIn: European Journal of Cancer (EJC), Jg. 228, 2025, 115750DOI (Open Access)
-
Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation statusIn: Frontiers in Immunology, Jg. 16, 2025, 1536642DOI, Online Volltext (Open Access)
-
Psychological Factors Influencing Appropriate Reliance on AI-enabled Clinical Decision Support Systems : Experimental Web-Based Study Among DermatologistsIn: Journal of Medical Internet Research (JMIR), Jg. 27, 2025, e58660DOI (Open Access)
-
pTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapyIn: European Journal of Cancer (EJC), Jg. 220, 2025, 115337DOI (Open Access)
-
A Systematic Comparison of Task Adaptation Techniques for Digital HistopathologyIn: Bioengineering, Jg. 11, 2024, Nr. 1, 19DOI (Open Access)
-
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanomaIn: European Journal of Cancer (EJC), Jg. 202, 2024, 113976DOI (Open Access)
-
BioKGrapher : Initial evaluation of automated knowledge graph construction from biomedical literatureIn: Computational and Structural Biotechnology Journal, Jg. 24, 2024, S. 639 – 660DOI (Open Access)
-
Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanomaIn: Frontiers in Immunology, Jg. 15, 2024, 1383125DOI (Open Access)
-
Early versus late response to PD-1-based immunotherapy in metastatic melanomaIn: European Journal of Cancer (EJC), Jg. 210, 2024, 114295DOI (Open Access)
-
Mitigating cognitive bias with clinical decision support systems : An experimental studyIn: Journal of Decision Systems, Jg. 33, 2024, Nr. 3, S. 439 – 458
-
Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A) : The doctors’ perspectiveIn: Journal of Cancer Research and Clinical Oncology, Jg. 150, 2024, Nr. 5, 252DOI (Open Access)
-
Requirements for a dashboard optimized for melanoma patient care through user-centered context explorationIn: Scientific Reports, Jg. 14, 2024, Nr. 1, 17471DOI (Open Access)
-
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomasIn: European Journal of Cancer (EJC), Jg. 208, 2024, 114208DOI (Open Access)
-
The Mappability of Clinical Real-World Data of Patients with Melanoma to Oncological Fast Healthcare Interoperability Resources (FHIR) Profiles : A Single-Center Interoperability StudyIn: Informatics, Jg. 11, 2024, Nr. 3, 42DOI, Online Volltext (Open Access)
-
Use of Real-World FHIR Data Combined with Context-Sensitive Decision Modeling to Guide Sentinel Biopsy in MelanomaIn: Journal of Clinical Medicine (JCM), Jg. 13, 2024, Nr. 11, 3353DOI (Open Access)
-
Adjuvant treatment and outcome of stage III melanoma patients : Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) studyIn: European Journal of Cancer (EJC), Jg. 191, 2023, 112957
-
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREGIn: Journal for ImmunoTherapy of Cancer, Jg. 11, 2023, Nr. 4DOI (Open Access)
-
COVID-19 vaccination in psoriasis patients receiving systemic treatment : A prospective single-center studyIn: Frontiers in Immunology, Jg. 14, 2023, S. 1107438DOI (Open Access)
-
Characterisation and outcome of RAC1 mutated melanomaIn: European Journal of Cancer (EJC), Jg. 183, 2023, S. 1 – 10
-
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma ADOREG/TRIM : Analysis of the DeCOG prospective multicenter cohort studyIn: eBioMedicine, Jg. 96, 2023, 104774DOI (Open Access)
-
Deep learning in computational dermatopathology of melanoma : A technical systematic literature reviewIn: Computers in Biology and Medicine, Jg. 163, 2023, 107083DOI (Open Access)
-
Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapyIn: Journal for ImmunoTherapy of Cancer, Jg. 11, 2023, Nr. 3, e006629DOI (Open Access)
-
Medikamentöse Therapie des inoperablen MelanomsIn: Die Onkologie, Jg. 29, 2023, Nr. 8, S. 680 – 686DOI (Open Access)
-
Prognostic factors in the primary care of patients with Merkel cell carcinoma : A monocentric cohort study of 108 patients from a tertiary referral centreIn: JEADV Clinical Practice, Jg. 2, 2023, Nr. 4, S. 810 – 818DOI, Online Volltext (Open Access)
-
The impact of the COVID-19 pandemic on the diagnosis of cutaneous melanomas : A retrospective cohort study from five European skin cancer reference centresIn: Journal of the European Academy of Dermatology and Venereology, Jg. 37, 2023, Nr. 5, Special issue on melanoma: Immune check point and BRAF‐MEK inhibitors in melanoma, S. 922 – 931DOI (Open Access)
-
Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy : A multicenter study from the prospective skin cancer registry ADOREGIn: Journal for ImmunoTherapy of Cancer, Jg. 11, 2023, Nr. 9, e007630DOI (Open Access)
-
COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment : A prospective singlecenter study investigating seroconversion ratesIn: Frontiers in Oncology, Jg. 12, 2022, 879876DOI, Online Volltext (Open Access)
-
Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia : divergent outcomes in two men treated with PD-1 inhibitorsIn: Journal of the European Academy of Dermatology and Venereology, Jg. 36, 2022, Nr. S1: Anti PD-1 Therapy of Advanced Cutaneous Squamous Cell Carcinoma, S. 41 – 44DOI (Open Access)
-
Clinical and pathological characteristics of familial melanoma with germline TERT promoter variantsIn: Pigment Cell and Melanoma Research, Jg. 35, 2022, Nr. 6, S. 573 – 586DOI (Open Access)
-
Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient SurvivalIn: Cancers, Jg. 14, 2022, Nr. 9, 2090DOI, Online Volltext (Open Access)
-
Genetic characterization of advanced conjunctival melanoma and response to systemic treatmentIn: European Journal of Cancer (EJC), Jg. 166, 2022, S. 60 – 72
-
Management of partial and non-responding cutaneous squamous cell carcinomaIn: Journal of the European Academy of Dermatology and Venereology, Jg. 36, 2022, Nr. S1, S. 29 – 34DOI (Open Access)
-
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapyIn: European Journal of Cancer (EJC), Jg. 161, 2022, S. 99 – 107DOI, Online Volltext (Open Access)
-
Validating Automatic Concept-Based Explanations for AI-Based Digital HistopathologyIn: Sensors, Jg. 22, 2022, Nr. 14, 5346DOI, Online Volltext (Open Access)
-
Computed tomography-guided biopsy of radiologically unclear lesions in advanced skin cancer : A retrospective analysis of 47 casesIn: European Journal of Cancer (EJC), Jg. 150, 2021, S. 119 – 129
-
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic MelanomaIn: Frontiers in Oncology, Jg. 11, 2021, 741993DOI, Online Volltext (Open Access)
-
Factors influencing the adjuvant therapy decision : Results of a real-world multicenter data analysis of 904 melanoma patientsIn: Cancers, Jg. 13, 2021, Nr. 10, S. 2319DOI, Online Volltext (Open Access)
-
GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular TumorsIn: Frontiers in Genetics, Jg. 12, 2021, 663272DOI, Online Volltext (Open Access)
-
Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphologyIn: European Journal of Cancer (EJC), Jg. 148, 2021, S. 340 – 347DOI, Online Volltext (Open Access)
-
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsIn: European Journal of Cancer (EJC), Jg. 159, 2021, S. 113 – 124
-
Rare TERT Promoter Mutations Present in Benign and Malignant Cutaneous Vascular TumorsIn: Dermato, Jg. 1, 2021, Nr. 1, S. 18 – 25DOI (Open Access)
-
Adjuvant treatment of patients with stage III melanoma : 4-year follow-up time of multicenter real-world study
ESMO Congress 2024, 13-17 September 2024, Barcelona, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 35, 2024, Nr. Suppl. 2, S. S740 -
Analysis of gender-specific Differences in Response to First-line Treatment with Immunotherapy or targeted Therapy in Melanoma Patients with metastatic Stage IV Melanoma : An ADO/DeCOG Study of 2032 Patients from the prospective, multicenter Skin Cancer Registry ADOREGIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 22, 2024, Nr. Suppl. 4, S. 16 – 17
-
Correlation of Laboratory Parameters at the Start of adjuvant Treatment of Stage III Melanoma Patients with clinical Outcome : A multicenter Real World StudyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 22, 2024, Nr. Suppl. 4, S. 8 – 9
-
Only early adjuvant radiotherapy, particularly of the tumor bed rather than the lymph node region, improves prognosis in Merkel cell carcinoma : Results from the prospective German MCC registry
ESMO Congress 2024, 13-17 September 2024, Barcelona, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 35, 2024, Nr. Suppl. 2, S. S744 -
PD-L1 Expression in Lymph Node Metastases as a Predictor of adjuvant Immunotherapy Success in Stage III Melanoma Patients: An Analysis of the prospective ADOREG Study TRIM-ADJUVANTIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 22, 2024, Nr. Suppl. 4, S. 15 – 16
-
Psychological Characteristics and their Impact on Trust in AI in dermatological Decision MakingIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 22, 2024, Nr. Suppl. 4, S. 34 – 35
-
The PD-L1 Expression predicts the Outcome of anti-PD-1/PD-L1-based Immune Checkpoint Therapy in Patients with metastatic Merkel Cell CarcinomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 22, 2024, Nr. Suppl. 4, S. 17 – 18
-
Die PD-L1-Expression im Tumor prognostiziert je nach Art des untersuchten Gewebes das Outcome einer Anti-PD-1-basierten Immuntherapie bei metastasiertem Melanom
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 21, 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 27 – 28DOI (Open Access) -
Molekulare und klinische Charakterisierung von BRAF/NRAS/NF1-wt Melanomen
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 21, 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 21DOI (Open Access) -
Treatment decision for melanoma patients : Identification of similar patients at point of care
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 21, 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO-Jahrestagung) 06.–09. September 2023 Hamburg, S. 5 – 6DOI (Open Access) -
Untersuchung des klinischen Verlaufs von Melanompatienten mit einer Super-Response (CR/PR innerhalb von 3 Monaten) unter PD-1-basierter Immuncheckpoint-Inhibition : eine Subgruppen-Analyse der prospektiven multizentrischen Studie ADOREG
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 21, 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 8 – 9DOI (Open Access) -
Development of brain metastases and survival outcomes upon first-line systemic therapy in BRAF mutant and BRAF wildtype melanoma patients : a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 20, 2022, Nr. S3, S. 13 – 14 -
Klinische und pathologische Merkmale des familiären Melanoms bei Keimbahn-TERT-Promotorvarianten
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 20, 2022, Nr. S3, S. 6 -
Multicenter real-world data of adjuvant treatment and disease outcome of patients with melanoma with high-risk of recurrenceIn: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 40, 2022, Nr. 16_Suppl., S. 9570DOI (Open Access)
-
Predictors of long-term survival of stage IV melanoma patients : a multicenter DeCOG study on 539 patients from the prospective skin cancer registry ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 20, 2022, Nr. S3, S. 16 – 17 -
Therapiemanagement des ersten Rezidivs nach adjuvanter Therapie im Stadium III : multizentrische real-world Daten
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 20, 2022, Nr. S3, S. 3 -
Efficacy of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy.In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 39, 2021, Nr. 15_Suppl., S. 9578 – 9578DOI (Open Access)
-
Predictors of Super-response (CR/PR within 3 Months) under PD-1-based Immune Checkpoint Inhibition in metastatic Melanoma : A Subgroup Analysis of the prospective multicenter Study ADOREG TRIMIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 19, 2021, Nr. Suppl. 4, S. 6 – 7
-
TERT Promoter Mutations associated with longer progression-free and Overall Survival under BRAF/MEK TherapyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 19, 2021, Nr. Suppl. 4, S. 31
-
Tumor PD-L1-Positivity in medical and digital Quantification predicts a favorable Patient Outcome for a PD-1-based Immune Checkpoint-Blockade in metastatic MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 19, 2021, Nr. Suppl. 4, S. 58 – 59
-
Guideline-Based Context-Sensitive Decision Modeling for Melanoma PatientsIn: German Medical Data Sciences 2022 – Future Medicine: More Precise, More Integrative, More Sustainable! / Joint Conference of the 67th Annual Meeting of the German Association of Medical Informatics, Biometry, and Epidemiology e.V. (gmds) and the 14th Annual Meeting of the TMF – Technology, Methods, and Infrastructure for Networked Medical Research e.V.; 21–25 August 2022; Kiel, Germany / Röhrig, Rainer; Grabe, Niels; Hoffmann, Verena S.; Hübner, Ursula; König, Jochem; Sax, Ulrich; Schreiweis, Björn; Sedlmayr, Martin (Hrsg.). Amsterdam: IOS Press, 2022, S. 50 – 57DOI (Open Access)
-
Supporting Dermatologists with Explainable Ai : Exploring the Effects of Consistency and Explanation Approaches2024
-
Identifizierung von nachteiligen Datensamples zur verbesserten KI-gestützten Klassifizierung von Hautläsionen unter Verwendung von Radiomics
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 21, 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 95 – 96DOI (Open Access) -
Melanom mit unbekanntem Primarius (MUP) - eine monozentrische Auswertung
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 21, 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 76 – 77DOI (Open Access) -
Pain points in software interaction in the treatment of melanoma patients
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 21, 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 125 – 126DOI (Open Access) -
Preliminary Examination of Cited Literature in International Melanoma Guidelines
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 21, 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 126DOI (Open Access) -
Context-Sensitive Modeling of a Standard Operating Procedure for Melanoma Patient Treatment
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 20, 2022, Nr. S3, S. 67 -
Explainable Radiomics by the example of malignant melanoma
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 20, 2022, Nr. S3, S. 65 – 66 -
Konzept-basierte Erklärung neuronaler Netze für die Dermatohistopathologie
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 20, 2022, Nr. S3, S. 68 -
Mitigating Cognitive Bias with Decision Support Systems
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 20, 2022, Nr. S3, S. 64 -
Molekularpathologie und Methylierungsprofile als diagnostische Unterstützung zur Differenzierung von Klarzellsarkomen und melanozytären Tumoren
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 20, 2022, Nr. S3, S. 88 -
Efficacy of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy
48th Annual Scientific Meeting Cancer care and research: Learning from the past and improving the future, 16-18 November 2021,In: Asia-Pacific Journal of Clinical Oncology: Wiley, Jg. 17, 2021, Nr. 9, SI, S. 162 – 163DOI (Open Access)